Laurus Labs Limited
Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and oral solid formulations for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It… Read more
Laurus Labs Limited (LAURUSLABS) - Total Liabilities
Latest total liabilities as of September 2025: ₹44.82 Billion INR
Based on the latest financial reports, Laurus Labs Limited (LAURUSLABS) has total liabilities worth ₹44.82 Billion INR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Laurus Labs Limited - Total Liabilities Trend (2013–2025)
This chart illustrates how Laurus Labs Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Laurus Labs Limited Competitors by Total Liabilities
The table below lists competitors of Laurus Labs Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
BofI Holding Inc
F:BB4
|
Germany | €25.27 Billion |
|
Universal Display Corp.
LSE:0LJE
|
UK | $211.84 Million |
|
Trex Company Inc
NYSE:TREX
|
USA | $410.00 Million |
|
CD Projekt S.A
PINK:OTGLF
|
USA | $237.60 Million |
|
Siegfried Holding AG
OTCGREY:SGFEF
|
USA | $953.81 Million |
Liability Composition Analysis (2013–2025)
This chart breaks down Laurus Labs Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.32 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.02 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.93 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.48 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Laurus Labs Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Laurus Labs Limited (2013–2025)
The table below shows the annual total liabilities of Laurus Labs Limited from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | ₹47.33 Billion | +10.81% |
| 2024-03-31 | ₹42.71 Billion | +18.27% |
| 2023-03-31 | ₹36.12 Billion | +0.08% |
| 2022-03-31 | ₹36.09 Billion | +14.57% |
| 2021-03-31 | ₹31.50 Billion | +59.05% |
| 2020-03-31 | ₹19.81 Billion | +11.72% |
| 2019-03-31 | ₹17.73 Billion | +15.56% |
| 2018-03-31 | ₹15.34 Billion | +15.96% |
| 2017-03-31 | ₹13.23 Billion | -8.84% |
| 2016-03-31 | ₹14.51 Billion | +29.36% |
| 2015-03-31 | ₹11.22 Billion | +22.63% |
| 2014-03-31 | ₹9.15 Billion | +105.95% |
| 2013-03-31 | ₹4.44 Billion | -- |